Table 3.
Use of COPD medication among COPD cases, in the last 7 days or the last 12 months prior to resurvey by gender, region, socioeconomic and smoking status
| Characteristics | Study population | Use of medication* (%, 95% CI) Last 7 days |
Use of medication† (%, 95% CI) Last 12 months |
| Participants | 1586 | 139 | 514 |
| Sex | |||
| Men | 772 | 9.6 (8.6 to 10.7) | 30.0 (28.5 to 31.6) |
| Women | 814 | 8.0 (7.0 to 8.9) | 34.6 (33.0 to 36.2) |
| Area | |||
| Rural (R) | 911 | 7.8 (6.9 to 8.7) | 30.6 (29.1 to 32.1) |
| Urban (U) | 675 | 10.1 (9.0 to 11.2) | 34.7 (32.9 to 36.5) |
| Regions‡ | |||
| Sichuan (R) | 265 | 7.0 (5.5 to 8.5) | 10.3 (8.5 to 12.2) |
| Harbin (U) | 183 | 10.8 (8.6 to 13.0) | 31.7 (28.3 to 35.1) |
| Gansu (R) | 173 | 10.4 (8.1 to 12.8) | 65.7 (62.1 to 69.3) |
| Liuzhou (U) | 216 | 10.5 (8.5 to 12.6) | 26.2 (23.3 to 29.2) |
| Henan (R) | 147 | 0.6 (0.0 to 1.2) | 14.9 (11.9 to 18.0) |
| Zhejiang (R) | 174 | 7.0 (5.0 to 8.9) | 22.8 (19.7 to 25.9) |
| Hunan (R) | 152 | 14.4 (11.4 to 17.3) | 49.8 (45.7 to 54.0) |
| Qingdao (U) | 81 | 10.5 (7.2 to 13.8) | 29.4 (24.4 to 34.4) |
| Suzhou (U) | 145 | 10.0 (7.7 to 12.4) | 51.5 (47.4 to 55.5) |
| Haikou (U) | 50 | 7.5 (4.1 to 11.0) | 40.9 (33.9 to 47.9) |
| Household income (¥) | |||
| <10 000 | 188 | 9.6 (7.7 to 11.4) | 35.1 (32.7 to 37.5) |
| 10 000–19 999 | 208 | 9.1 (7.6 to 10.6) | 36.2 (33.8 to 38.6) |
| ≥20 000 | 1190 | 8.7 (8.2 to 9.3) | 31.9 (31.0 to 32.8) |
| Education | |||
| None | 326 | 8.5 (7.1 to 9.8) | 31.1 (28.6 to 33.6) |
| Primary | 530 | 9.3 (8.3 to 10.3) | 36.8 (35.4 to 38.3) |
| Secondary or tertiary | 730 | 8.2 (7.4 to 8.9) | 28.3 (27.1 to 29.5) |
| Smoking status | |||
| Never | 984 | 9.0 (8.2 to 9.7) | 32.0 (30.9 to 33.0) |
| Ex-regular | 177 | 17.0 (14.6 to 19.4) | 39.4 (36.5 to 42.3) |
| Current regular | 425 | 8.3 (6.6 to 10.0) | 27.1 (24.9 to 29.4) |
*Medication questionnaire was completed only by those who had symptom-based COPD or history of doctor diagnosed COPD in the second resurveys; medication in last 7 days (short-acting bronchodilators, long-acting bronchodilators, oral bronchodilators, any inhaled medications, traditional Chinese medicine and any other treatments prescribed for COPD).
†Medication in last 12 months (antibiotics, oral corticosteroids, injectable corticosteroids). Standardised for region, age group and gender as appropriate.
‡The regions are ordered by COPD prevalence as in figure 3.
COPD, chronic obstructive pulmonary disease.